Drug General Information
Drug ID
D0SG7B
Former ID
DIB015232
Drug Name
GLPG-0634
Synonyms
Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK
Drug Type
Small molecular drug
Indication Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] Phase 2 [524620], [542835]
Company
Abbvie; galapagos
Structure
Download
2D MOL

3D MOL

Formula
C21H23N5O3S
InChI
InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)
InChIKey
RIJLVEAXPNLDTC-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) JAK1 Target Info Modulator [532469], [532777]
KEGG Pathway PI3K-Akt signaling pathway
Osteoclast differentiation
Signaling pathways regulating pluripotency of stem cells
Jak-STAT signaling pathway
Leishmaniasis
Toxoplasmosis
Tuberculosis
Hepatitis C
Hepatitis B
Measles
Influenza A
HTLV-I infection
Herpes simplex infection
Epstein-Barr virus infection
Pathways in cancer
Viral carcinogenesis
Pancreatic cancer
NetPath Pathway IL2 Signaling Pathway
PANTHER Pathway Angiogenesis
Interferon-gamma signaling pathway
JAK/STAT signaling pathway
PDGF signaling pathway
Pathway Interaction Database p73 transcription factor network
IL4-mediated signaling events
IL27-mediated signaling events
Signaling events mediated by TCPTP
SHP2 signaling
IL2-mediated signaling events
IL2 signaling events mediated by PI3K
IFN-gamma pathway
IL6-mediated signaling events
PDGFR-alpha signaling pathway
IL2 signaling events mediated by STAT5
Reactome Interleukin-6 signaling
MAPK3 (ERK1) activation
MAPK1 (ERK2) activation
GPVI-mediated activation cascade
ISG15 antiviral mechanism
Interleukin-7 signaling
G beta:gamma signalling through PI3Kgamma
Interleukin-2 signaling
RAF/MAP kinase cascade
Interferon gamma signaling
Regulation of IFNG signaling
Interferon alpha/beta signaling
Interleukin receptor SHC signaling
Regulation of IFNA signaling
WikiPathways Type II interferon signaling (IFNG)
Interferon type I signaling pathways
TGF Beta Signaling Pathway
IL-2 Signaling Pathway
IL-4 Signaling Pathway
IL-6 signaling pathway
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
IL-3 Signaling Pathway
Interleukin-2 signaling
Interleukin-7 signaling
JAK/STAT
PDGF Pathway
Oncostatin M Signaling Pathway
Interleukin-11 Signaling Pathway
Prostate Cancer
TSLP Signaling Pathway
IL-9 Signaling Pathway
Type III interferon signaling
IL17 signaling pathway
IL-7 Signaling Pathway
Leptin signaling pathway
TSH signaling pathway
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Interleukin-3, 5 and GM-CSF signaling
Interferon gamma signaling
Interferon alpha/beta signaling
IL-5 Signaling Pathway
References
Ref 524620ClinicalTrials.gov (NCT02048618) Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease. U.S. National Institutes of Health.
Ref 542835(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7913).
Ref 532469Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013 Oct 1;191(7):3568-77.
Ref 532777Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.